Dal Canton Antonio, Amore Amore, Barbano Giancarlo, Coppo Rosanna, Emma Francesco, Grandaliano Giuseppe, Klersy Catherine, Perfumo Francesco, Rizzoni Gianfranco, Schena Francesco Paolo, Sepe Vincenzo
Unit of Nephrology, Dialysis and Transplantation, IRCCS Policlinico San Matteo and University of Pavia, Pavia.
J Nephrol. 2005 Mar-Apr;18(2):136-40.
Angiotensin converting-enzyme inhibition (ACEI) is a widely accepted treatment during established renal diseases and beneficial effects have also been reported in IgA nephropathy (IgAN). Immunosuppression with myco-phenolate mofetil (MMF) has recently been introduced in the treatment of immune-mediated renal diseases showing promising results. Preliminary clinical reports are also suggestive that MMF is effective in severe forms of IgAN. We propose a randomised prospective trial aimed to compare long-term renal survival of early IgAN in the course of ACEI therapy with or without MMF immunosuppression.
